



UK CLL Forum Clinical Sciences Day

Wednesday 22nd September 2010

Royal Institute of British Architects, 66 Portland Place, London W1B 1AD

Clinical and Immunological Challenges in CLL

This meeting is kindly sponsored by an unrestricted educational grant from:

Gold Sponsors



Silver Sponsors



Supporters

Lipomed GmbH

Genopharm

Meeting endorsed by



09.30 *Registration and coffee*

Morning session

10.00 Importance of first-line therapy in improving overall survival in CLL: conclusions from long-time follow-up of a large North American Inter-Group randomized study (*Roche sponsored session*)

10.40 Immunology support for CLL (*Baxter sponsored session*)

11.15 The challenges in the management of CLL (*GSK sponsored session*)

11.45 Lenalidomide: A novel agent in the treatment of CLL (*Celgene sponsored session*)

12.15 UK CLL Forum AGM (see over for agenda)

12.30 *Lunch*

Afternoon session

13.15 Immunotherapeutic reversal of T cell dysfunction in CLL: a mouse modelling approach

13.45 Graft versus leukaemia mechanisms: lessons from CLL

Catovsky prize presentations:

14.15 Preclinical evaluation of a type II CD20 monoclonal antibody (GA101) in CLL

14.30 A putative role for DNA-PK in the regulation of NF- κ B activity in chronic lymphocytic leukaemia (CLL)

14.45 Genome-wide profiling of chromosomal imbalances in CLL

15.00 The PARP inhibitor olaparib induces significant killing of ATM deficient tumour cells *in vitro* and *in vivo*

15.15 *Coffee break*

15.45 Allogenic transplant for poor risk CLL

16.30 *Close*

Chair: Dr George Follows

Dr Kanti Rai
*Long Island Jewish Medical Centre
New York*

Dr Andrew Exley
Papworth Hospital, Cambridge

Dr Anna Schuh
Churchill Hospital, Oxford

Professor John Gribben
Barts and The London

Chair: Dr Chris Fegan

Chair: Professor Andy Pettitt

Professor John Gribben
Barts and The London

Professor Paul Moss
University of Birmingham

Mr Alex Fisher
*MRC Toxicology
University of Leicester*

Dr Evan Mulligan
*Newcastle Cancer Centre
Newcastle University*

Dr Jonathan Strefford
*School of Medicine
University of Southampton*

Dr Victoria Weston
*CRUK School of Cancer Sciences
Birmingham University*

Dr Johannes Schetelig
*University Hospital Carl Gustav Carus
Germany*

Baxter, Celgene, GSK and Roche have provided an additional financial contribution to the UK CLL Forum for sponsored sessions at this meeting, including speaker expenses. They were involved in planning the morning session through suggesting speakers and topics. All sessions have had the final approval of the UKCLL Forum sub-group programme planning committee. GSK has had no input into, or oversight of, the content of the GSK-sponsored educational talk



UK CLL Forum

Annual General Meeting

Royal Institute of British Architects (RIBA), 66 Portland Place,
London W1B 1AD

Wednesday 22nd September 2010

12.15 – 12.30

AGENDA

- | | |
|-----------------------|---------------------------------|
| 1. Chairman's report | Andy Pettitt |
| 2. Treasurer's report | Chris Fegan |
| 3. Website | Steve Devereux/ Aneela Majid |